| Michael F Malizzo, MD | |
|
2901 Transport St Se, Albuquerque, NM 87106-4382 | |
| (505) 262-7724 | |
| (505) 262-5697 |
| Full Name | Michael F Malizzo |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 31 Years |
| Location | 2901 Transport St Se, Albuquerque, New Mexico |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538182647 | NPI | - | NPPES |
| 85338257 | Medicaid | NM |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Optumcare New Mexico Llc | 9032125810 | 68 |
News Archive
Cell biologists at the Ruhr-Universit-t Bochum have launched a new project to unravel the role of the enzyme Parkin in promoting neuronal survival. The team of Prof Dr Konstanze F. Winklhofer from the Institute of Physiological Chemistry, Department of Molecular Cell Biology, is looking for new therapeutic options to treat Parkinson's disease. The Michael J. Fox Foundation finances this research project with 125,000 US Dollars.
Scientists at Sanford-Burnham Medical Research Institute today announced the discovery that a gene encoding an enzyme, phosphoinositide-dependent kinase-1, plays an essential role in the development and progression of melanoma. The finding offers a new approach to treating this life-threatening disease.
Eribis Pharmaceuticals AB - part of the Karolinska Development portfolio - announced today that it has received follow-on financial investment enabling the company to continue its clinical development program. Based on cardio-protective effects, Eribis' candidate drug has the potential to become an important new therapy for treating acute coronary syndrome (ACS) and reperfusion injury (damage to tissue caused when blood supply returns after a period of ischemia), as well as for surgical preconditioning. The new round of investment from Karolinska Development AB will allow Eribis to strengthen the preclinical material.
For a long time, scientists have dreamt of converting undesirable white fat cells into brown fat cells and thus simply have excess pounds melt away. Researchers at the University of Bonn have now gotten a step closer to this goal: They decoded a "toggle switch" in mice which can significantly stimulate fat burning.
Numerate, Inc. announced today that it has been awarded a new three-year contract by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense, to adapt its pioneering small-molecule drug design platform to the rapid design and optimization of drugs against biowarfare agents.
› Verified 8 days ago
| Entity Name | Optumcare New Mexico Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124053210 PECOS PAC ID: 9032125810 Enrollment ID: O20060302000704 |
News Archive
Cell biologists at the Ruhr-Universit-t Bochum have launched a new project to unravel the role of the enzyme Parkin in promoting neuronal survival. The team of Prof Dr Konstanze F. Winklhofer from the Institute of Physiological Chemistry, Department of Molecular Cell Biology, is looking for new therapeutic options to treat Parkinson's disease. The Michael J. Fox Foundation finances this research project with 125,000 US Dollars.
Scientists at Sanford-Burnham Medical Research Institute today announced the discovery that a gene encoding an enzyme, phosphoinositide-dependent kinase-1, plays an essential role in the development and progression of melanoma. The finding offers a new approach to treating this life-threatening disease.
Eribis Pharmaceuticals AB - part of the Karolinska Development portfolio - announced today that it has received follow-on financial investment enabling the company to continue its clinical development program. Based on cardio-protective effects, Eribis' candidate drug has the potential to become an important new therapy for treating acute coronary syndrome (ACS) and reperfusion injury (damage to tissue caused when blood supply returns after a period of ischemia), as well as for surgical preconditioning. The new round of investment from Karolinska Development AB will allow Eribis to strengthen the preclinical material.
For a long time, scientists have dreamt of converting undesirable white fat cells into brown fat cells and thus simply have excess pounds melt away. Researchers at the University of Bonn have now gotten a step closer to this goal: They decoded a "toggle switch" in mice which can significantly stimulate fat burning.
Numerate, Inc. announced today that it has been awarded a new three-year contract by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense, to adapt its pioneering small-molecule drug design platform to the rapid design and optimization of drugs against biowarfare agents.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael F Malizzo, MD Po Box 26028, Albuquerque, NM 87125-6028 Ph: (505) 232-1617 | Michael F Malizzo, MD 2901 Transport St Se, Albuquerque, NM 87106-4382 Ph: (505) 262-7724 |
News Archive
Cell biologists at the Ruhr-Universit-t Bochum have launched a new project to unravel the role of the enzyme Parkin in promoting neuronal survival. The team of Prof Dr Konstanze F. Winklhofer from the Institute of Physiological Chemistry, Department of Molecular Cell Biology, is looking for new therapeutic options to treat Parkinson's disease. The Michael J. Fox Foundation finances this research project with 125,000 US Dollars.
Scientists at Sanford-Burnham Medical Research Institute today announced the discovery that a gene encoding an enzyme, phosphoinositide-dependent kinase-1, plays an essential role in the development and progression of melanoma. The finding offers a new approach to treating this life-threatening disease.
Eribis Pharmaceuticals AB - part of the Karolinska Development portfolio - announced today that it has received follow-on financial investment enabling the company to continue its clinical development program. Based on cardio-protective effects, Eribis' candidate drug has the potential to become an important new therapy for treating acute coronary syndrome (ACS) and reperfusion injury (damage to tissue caused when blood supply returns after a period of ischemia), as well as for surgical preconditioning. The new round of investment from Karolinska Development AB will allow Eribis to strengthen the preclinical material.
For a long time, scientists have dreamt of converting undesirable white fat cells into brown fat cells and thus simply have excess pounds melt away. Researchers at the University of Bonn have now gotten a step closer to this goal: They decoded a "toggle switch" in mice which can significantly stimulate fat burning.
Numerate, Inc. announced today that it has been awarded a new three-year contract by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense, to adapt its pioneering small-molecule drug design platform to the rapid design and optimization of drugs against biowarfare agents.
› Verified 8 days ago
Matthew Steven Bergsten, M.D. Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 3600 Coors Blvd Nw Ste 200, Albuquerque, NM 87120 Phone: 575-395-7246 | |
Timothy Earl Hansen, D.O. Pain Medicine Medicare: Not Enrolled in Medicare Practice Location: 3860 Masthead St Ne, Albuquerque, NM 87109 Phone: 505-828-1010 Fax: 505-796-9051 | |
John A Campa Iii, MD Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 7520 Montgomery Blvd Ne Bldg E4, Albuquerque, NM 87109 Phone: 505-508-1543 Fax: 505-554-2118 | |
Dr. Craig Stephen Nairn, M.D. Pain Medicine Medicare: May Accept Medicare Assignments Practice Location: 8080 Academy Rd Ne, Suite A, Albuquerque, NM 87111 Phone: 505-247-9700 Fax: 505-247-4333 |